Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Cosette Pharmaceuticals announced the acquisition of the SYMPAZAN, INDOCIN, SPRIX, CAMBIA, ZIPSOR and OTREXUP product franchises from Assertio Holdings for an…
Zydus Lifesciences Limited announced that its subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire all outstanding shares of Assertio…
Assertio Holdings filed a Form 8-K announcing entry into an Agreement and Plan of Merger with Zydus Worldwide DMCC and Zoom Merger Sub Inc. providing for the…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Zydus Worldwide DMCC (subsidiary of Zydus Lifesciences) entered a definitive agreement to acquire Assertio Holdings for $23.50/share cash, total consideration ~$166.4M, after Assertio's board deemed Zydus's bid a Superior Proposal over Garda Therapeutics' competing $21.80/share offer (Garda agreement terminated). Adds Assertio's US specialty/oncology supportive-care portfolio (Indocin, Sympazan, Otrexup, Sympan, Rolvedon).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Zydus Lifesciences Limited / Assertio Holdings, Inc. (this deal) | 2026 | $166M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 2026 deals · Immunology deals